Historical Valuation
SAB Biotherapeutics Inc (SABS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -9.28. The fair price of SAB Biotherapeutics Inc (SABS) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 3.68 USD , SAB Biotherapeutics Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：3.68
Fair
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
SAB Biotherapeutics Inc (SABS) has a current Price-to-Book (P/B) ratio of 1.08. Compared to its 3-year average P/B ratio of 1.20 , the current P/B ratio is approximately -9.45% higher. Relative to its 5-year average P/B ratio of 2.89, the current P/B ratio is about -62.41% higher. SAB Biotherapeutics Inc (SABS) has a Forward Free Cash Flow (FCF) yield of approximately -20.94%. Compared to its 3-year average FCF yield of -102.62%, the current FCF yield is approximately -79.59% lower. Relative to its 5-year average FCF yield of -72.00% , the current FCF yield is about -70.92% lower.
P/B
Median3y
1.20
Median5y
2.89
FCF Yield
Median3y
-102.62
Median5y
-72.00
Competitors Valuation Multiple
AI Analysis for SABS
The average P/S ratio for SABS competitors is 149.84, providing a benchmark for relative valuation. SAB Biotherapeutics Inc Corp (SABS.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SABS
1Y
3Y
5Y
Market capitalization of SABS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SABS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SABS currently overvalued or undervalued?
SAB Biotherapeutics Inc (SABS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -9.28. The fair price of SAB Biotherapeutics Inc (SABS) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 3.68 USD , SAB Biotherapeutics Inc is Undervalued By Fair .
What is SAB Biotherapeutics Inc (SABS) fair value?
SABS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of SAB Biotherapeutics Inc (SABS) is between +Inf to +Inf according to relative valuation methord.
How does SABS's valuation metrics compare to the industry average?
The average P/S ratio for SABS's competitors is 149.84, providing a benchmark for relative valuation. SAB Biotherapeutics Inc Corp (SABS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for SAB Biotherapeutics Inc (SABS) as of Jan 10 2026?
As of Jan 10 2026, SAB Biotherapeutics Inc (SABS) has a P/B ratio of 1.08. This indicates that the market values SABS at 1.08 times its book value.
What is the current FCF Yield for SAB Biotherapeutics Inc (SABS) as of Jan 10 2026?
As of Jan 10 2026, SAB Biotherapeutics Inc (SABS) has a FCF Yield of -20.94%. This means that for every dollar of SAB Biotherapeutics Inc’s market capitalization, the company generates -20.94 cents in free cash flow.
What is the current Forward P/E ratio for SAB Biotherapeutics Inc (SABS) as of Jan 10 2026?
As of Jan 10 2026, SAB Biotherapeutics Inc (SABS) has a Forward P/E ratio of -4.73. This means the market is willing to pay $-4.73 for every dollar of SAB Biotherapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for SAB Biotherapeutics Inc (SABS) as of Jan 10 2026?
As of Jan 10 2026, SAB Biotherapeutics Inc (SABS) has a Forward P/S ratio of 0.00. This means the market is valuing SABS at $0.00 for every dollar of expected revenue over the next 12 months.